Swiss drugmaker Roche said on Wednesday it had entered into an agreement with QIAGEN that includes a provision of non-exclusive licenses to recently granted Roche patents, pertaining to the detection of mutations in the EGFR pathway.
{iframe}http://www.reuters.com/article/2015/01/14/roche-qiagen-idUSFWN0UR05820150114{/iframe}